Trade Report: The Ritter Pharmaceuticals’ (RTTR) Buy Rating Reaffirmed at Maxim Group

The Ritter Pharmaceuticals’ (RTTR) Buy Rating Reaffirmed at Maxim Group

Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Monday.

Separately, Zacks Investment Research lowered Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 14th.

Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 10.00% during midday trading on Monday, hitting $1.87. The stock had a trading volume of 25,927 shares. The stock has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.53. Ritter Pharmaceuticals has a one year low of $0.98 and a one year high of $2.63. The firm’s market cap is $16.05 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.14. On average, analysts predict that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current year.

Ritter Pharmaceuticals Company Profile

Related posts

Leave a Comment